dc.contributor.author | Wilson, BE | |
dc.contributor.author | Armstrong, AJ | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Sternberg, CN | |
dc.contributor.author | Ryan, CJ | |
dc.contributor.author | Scher, HI | |
dc.contributor.author | Smith, MR | |
dc.contributor.author | Rathkopf, D | |
dc.contributor.author | Logothetis, CJ | |
dc.contributor.author | Chi, KN | |
dc.contributor.author | Jones, RJ | |
dc.contributor.author | Saad, F | |
dc.contributor.author | De Porre, P | |
dc.contributor.author | Tran, N | |
dc.contributor.author | Hu, P | |
dc.contributor.author | Gillessen, S | |
dc.contributor.author | Carles, J | |
dc.contributor.author | Fizazi, K | |
dc.contributor.author | Joshua, AM | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-09-05T09:34:45Z | |
dc.date.available | 2022-09-05T09:34:45Z | |
dc.date.issued | 2022-07-01 | |
dc.identifier | S0959-8049(22)00205-2 | |
dc.identifier.citation | European Journal of Cancer, 2022, 170 pp. 296 - 304 | en_US |
dc.identifier.issn | 0959-8049 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5402 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.eissn | 1879-0852 | |
dc.identifier.doi | 10.1016/j.ejca.2022.03.042 | |
dc.description.abstract | BACKGROUND: The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. OBJECTIVE: To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR. DESIGN, SETTING AND PARTICIPANT: COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use. Cox proportional hazards models were used to estimate hazards ratio (HR) stratified by concomitant medications, and a random effects model was used to pool HR. We compared PSA-RR using Chi χ2 test. RESULTS: In COU-AA-301-AAP, metformin was associated with improved PSA-RR (41.1% versus 28.6%) but not prolonged OS. In COU-AA-301-placebo-P, there was no association between metformin and prolonged OS or PSA-RR. In COU-AA-302-AAP, metformin was associated with prolonged OS (adjHR 0.69, 95% CI 0.48-0.98) and improved PSA-RR (72.7% versus 60.0%). In COU-AA-302-P, metformin was associated with prolonged OS (adjHR 0.66, 95% CI 0.47-0.93). In pooled analysis, OS was prolonged among those treated with metformin (pooled HR 0.77, 95% CI 0.62-0.95).In COU-AA-301-AAP, statins were associated with an improved OS (adjHR 0.76, 95% CI 0.62-0.93), while there was no difference in COU-AA-301-P. There was no association with statins and OS in either COU-AA-302 groups. When pooling HR, OS was prolonged among those treated with statins (pooled HR 0.78, 95% CI 0.68-0.88). CONCLUSION: Within the limitations of post-hoc sub-analyses, metformin and statins are associated with a prolonged OS and increased PSA-RR, particularly in combination with AAP. | |
dc.format | Print-Electronic | |
dc.format.extent | 296 - 304 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER SCI LTD | en_US |
dc.relation.ispartof | European Journal of Cancer | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Abiraterone acetate | |
dc.subject | Metastatic castration-resistant prostate cancer | |
dc.subject | Metformin | |
dc.subject | Statins | |
dc.subject | Abiraterone Acetate | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Castration | |
dc.subject | Disease-Free Survival | |
dc.subject | Humans | |
dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors | |
dc.subject | Male | |
dc.subject | Metformin | |
dc.subject | Prednisone | |
dc.subject | Prostate-Specific Antigen | |
dc.subject | Prostatic Neoplasms, Castration-Resistant | |
dc.subject | Treatment Outcome | |
dc.title | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-03-16 | |
dc.date.updated | 2022-09-05T09:33:38Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.ejca.2022.03.042 | en_US |
rioxxterms.licenseref.startdate | 2022-07-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35568679 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.ejca.2022.03.042 | |
pubs.volume | 170 | |
icr.researchteam | PrCa Targeted Therapy | en_US |
dc.contributor.icrauthor | De Bono, Johann | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-05. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0959804922002052-main.pdf | |